Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | KAT8 | Q9H7Z6 | 4/20 | 0.53 |
| ▸ | BID | P55957 | 3/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.53 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.53 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.53 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.53 |
| ▸ | RARA | P10276 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17625912 | 1.00 | PPARA (0.56) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL5268382 | 1.00 | PPARA (0.56) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL5268409 | 1.00 | PPARA (0.56) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL5270072 | 1.00 | PPARA (0.56) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL17625900 | 1.00 | PPARA (0.56) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL28465098 | 1.00 | PPARA (0.56) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL5272862 | 1.00 | PPARA (0.56) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL7521299 | 0.98 | PPARA (0.54) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL11868796 | 0.87 | PPARA (0.54) | PPARATYRKAT8BIDMCL1 | |
| SCHEMBL7568852 | 0.87 | BID (0.57) | PPARATYRKAT8BIDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1243609-B1 | SUCCINIMIDE COMPOUNDS AND USE THEREOF | IDEMITSU KOSAN CO (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-6906191-B2 | Succinimide compounds and use thereof | IDEMITSU KOSAN CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20030018198-A1 | Succinimide compounds and use thereof | IDEMITSU KOSAN CO., LTD. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1243609-A1 | SUCCINIMIDE COMPOUNDS AND USE THEREOF | IDEMITSU KOSAN CO., LTD. (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018198-A1 | Succinimide compounds and use thereof | SRM, SMS, SGMS2 | PPARA 681/4885TYR 3411/4885KAT8 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.